[1] Bassukas ID. Comparative gompertzian analysis of alterations of tumor growth patterns. Cancer Res 1994, Aug 15; 54(16): 4385-92.

[2] Demicheli R, Foroni R, Ingrosso A, Pratesi G, Soranzo C, Tortoreto M. An exponen-tial-gompertzian description of lovo cell tumor growth from in vivo and in vitro data. Cancer Res 1989, Dec 1; 49(23): 6543-6.

[3] Norton L. A gompertzian model of human breast cancer growth. Cancer Res 1988, Dec 15;48(24 Pt 1):7067-71.

[4] Mottram JC. On the correlation between malignancy and the rate of growth of tar warts in mice. Cancer Res 1934, Dec; 22(4): 801-30.

[5] Mottram JC. A further consideration of the growth rates of tar warts in mice and of their autografts. The American Journal of Cancer 1936; 28(1): 115-20.

[6] Laird AK. Dynamics of normal growth. Annual Report 1964; 6971:52.

[7] Laird AK. Dynamics of tumour growth: Comparison of growth rates and extrapolation of growth curve to one cell. Br J Cancer 1965; 19(2): 278.

[8] Friberg S, Mattson S. On the growth rates of human malignant tumors: Implications for medical decision-making. J Surg Oncol 1997, Aug; 65(4): 284-97.

[9] Collins VP, Loeffler RK, Tivey H. Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med 1956, Nov; 76(5): 988-1000.

[10] Schwartz M. A biomathematical approach to clinical tumor growth. Cancer 1961; 14:1272-94.

[11] Spratt JS, Spjut HJ, Roper CL. The frequency distribution of the rates of growth and the estimated duration of primary pulmonary carcinomas. Cancer 1963, Jun; 16:687-93.

[12] Spratt Jr JS, Spratt TL. Rates of growth of pulmonary metastases and host survival. Ann Surg 1964; 159(2): 161.

[13] Steel GG, Lamerton LF. The growth rate of human tumours. Br J Cancer 1966, Mar; 20(1): 74-86.

[14] Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, Carter HB. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: Data from the Baltimore longitudinal study of aging. Eur Urol 2008, Nov; 54(5): 1073-80.

[15] Tosoian J, Loeb S. PSA and beyond: The past, present, and future of investigative bio-markers for prostate cancer. ScientificWorldJournal 2010; 10:1919-31.

[16] Klotz L, Teahan S. Current role of PSA kinetics in the management of patients with prostate cancer. European Urology Supplements 2006, Apr; 5(6): 472-8.

[17] D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004, Jul 8; 351(2): 125-35.

[18] D'Amico AV, Chen MH, de Castro M, Loffredo M, Lamb DS, Steigler A, et al. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: An analysis of two randomised trials. Lancet Oncol 2012, Feb; 13(2): 189-95.

[19] Miyamoto S. A chronological study of hepatic metastasis from colorectal cancer. Jpn J Gastroenterol Sur 1991;24:1990-6.

[20] Kato RB, Srougi V, Salvadori FA, Ayres PP, Leite KM, Srougi M. Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer. Clinics (Sao Paulo) 2008, Dec; 63(6): 759-62.

[21] Babaian RJ, Troncoso P, Steelhammer LC, Lloreta-Trull J, Ramirez EI. Tumor volume and prostate specific antigen: Implications for early detection and defining a window of curability. J Urol 1995, Nov; 154(5): 1808-12.

[22] Tanaka N, Fujimoto K, Hirayama A, Nakai Y, Chihara Y, Anai S, et al. Calculated tumor volume is an independent predictor of biochemical recurrence in patients who underwent retropubic radical prostatectomy. Adv Urol 2012; 2012:204215.

[23] Vollmer RT, Humphrey PA. Tumor volume in prostate cancer and serum prostate-specific antigen. Analysis from a kinetic viewpoint. Am J Clin Pathol 2003, Jan; 119(1): 80-9.

[24] Carter HB, Pearson JD, Waclawiw Z, Metter EJ, Chan DW, Guess HA, Walsh PC. Prostate-specific antigen variability in men without prostate cancer: Effect of sampling interval on prostate-specific antigen velocity. Urology 1995, Apr; 45(4): 591-6.

[25] Van den Bergh RC, Roemeling S, Roobol MJ, Wolters T, Schröder FH, Bangma CH. Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review. Eur Urol 2008, Sep; 54(3): 505-16.

[26] Ramirez ML, Nelson EC, Devere White RW, Lara PN, Evans CP. Current applications for prostate-specific antigen doubling time. Eur Urol 2008, Aug; 54(2): 291-300.

[27] Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog 2011; 10:20.

[28] Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999, Oct; 45(10): 1695-707.

[29] Nash AF, Melezinek I. The role of prostate specific antigen measurement in the detection and management of prostate cancer. Endocr Relat Cancer 2000, Mar; 7(1): 37-51.

[30] Ryan CJ, Smith A, Lal P, Satagopan J, Reuter V, Scardino P, et al. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression. Urology 2006;68(4):834-9.

[31] Kelloff GJ, Coffey DS, Chabner BA, Dicker AP, Guyton KZ, Nisen PD, et al. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res 2004, Jun 1; 10(11): 3927-33.

[32] Oudard S, Banu E, Scotte F, Banu A, Medioni J, Beuzeboc P, et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007, Nov; 18(11): 1828-33.

[33] Newling DW. Issues with the use of prostate-specific antigen as a surrogate end point in hormone-resistant prostate cancer. European Urology Supplements 2009, Jan;8(1): 13-9.

[34] Singh AK, Guion P, Susil RC, Citrin DE, Ning H, Miller RW, et al. Early observed transient prostate-specific antigen elevations on a pilot study of external beam radiation therapy and fractionated MRI guided high dose rate brachytherapy boost. Radiat Oncol 2006; 1:28.

[35] Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group. J Clin Oncol 1999, Nov; 17(11): 3461-7.

[36] WOO TCS, Richard Choo MD, Mary Jamieson RN, Chander BSNDS. Vitamin D3 (cholecalciferol) in the treatment of biochemically-relapsed prostate cancer. .

[37] Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: A phase II pilot study. Prostate Cancer Prostatic Dis 2003;6(4):301-4.

[38] Guess B, Jennrich R, Johnson H, Redheffer R, Scholz M. Using splines to detect changes in PSA doubling times. Prostate 2003, Feb 1; 54(2): 88-94.

[39] Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of canada. J Natl Cancer Inst 2000, Feb 2; 92(3): 205-16.

[40] Therasse, P. Response assessment in cancer clinical trials. Doctorate thesis; Erasmus University, Rotterdam, 2006.

[41] Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005, Jul 27; 294(4): 433-9.

[42] Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 2012, Mar; 61(3): 549-59.

[43] Gupta S, Carballido E, Fishman M. Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: An update and perspective among other treatments. Onco Targets Ther 2011; 4:79-96.

[44] Garcia JA. Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: An insight for oncologists. Ther Adv Med Oncol 2011, Mar; 3(2): 101-8.

[45] Bitting RL, Armstrong AJ, George DJ. Management options in advanced prostate cancer: What is the role for sipuleucel-t? Clinical Medicine Insights: Oncology; 5:325-32.

[46] Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011, Feb 15; 17(4): 907-17.

[47] Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol 2012, Jun; 39(3): 296-304.

[48] Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993, Apr; 11(4): 607-15.

[49] Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. Journal of Clinical Oncology 1998; 16(5): 1835-43.

[50] Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008, Jan 10; 26(2): 242-5.

[51] Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF, TAX 327 Investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008, Oct; 19(10): 1749-53.

[52] Heidenreich A, Bolla M, Joniau S, Van Der Kwast TH, Matveev V, Mason MD, et al. Guidelines on prostate cancer. Eur Urol 2008; 53(1): 68-80.

[53] Bellmunt J, Rosenberg JE, Choueiri TK. Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. Eur Urol 2009; 56(4): 606.

[54] Loriot Y, Massard C, Fizazi K. Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. Ann Oncol 2012, May; 23(5): 1085-94.

[55] Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008, Jan 1; 14(1): 209-14.

[56] Thuret R, Massard C, Gross-Goupil M, Escudier B, Di Palma M, Bossi A, et al. The postchemotherapy PSA surge syndrome. Ann Oncol 2008, Jul; 19(7): 1308-11.

[57] Chi KN, Ellard SL, Hotte SJ, Czaykowski P, Moore M, Ruether JD, et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 2008, Apr; 19(4): 746-51.

[58] Bellmunt J, Rosenberg JE, Choueiri TK. Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. Eur Urol 2009; 56(4): 606.

[59] Bellmunt J, Oh WK. Castration-resistant prostate cancer: New science and therapeutic prospects. Ther Adv Med Oncol 2010, May; 2(3): 189-207.

[60] Rixe O, Fojo T. Is cell death a critical end point for anticancer therapies or is cytosta-sis sufficient? Clin Cancer Res 2007, Dec 15; 13(24): 7280-7.

[61] Nabhan C, Tolzien K, Lestingi T, Kelby SK, Galvez AG, Bitran JD. Activity of sorafenib (SOR) in chemotherapy-failure castration-resistant prostate cancer (CRPC). AS-CO/GU Proceedings 2010; 122.

[62] Carmichael C, Lau C, Josephson DY, Pal SK. Comprehensive overview of axitinib development in solid malignancies: Focus on metastatic renal cell carcinoma. Clin Adv Hematol Oncol 2012 May; 10(5): 307-14.

[63] Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, Feb 9; 366(6): 520-9.

[64] Kung HJ. Targeting tyrosine kinases and autophagy in prostate cancer. Horm Cancer 2011, Feb; 2(1): 38-46.

[65] Adamo V, Noto L, Franchina T, Chiofalo G, Picciotto M, Toscano G, Caristi N. Emerging targeted therapies for castration-resistant prostate cancer. Front Endocri-nol (Lausanne) 2012; 3:73.

[66] Agarwal N, Sonpavde G, Sternberg CN. Novel molecular targets for the therapy of castration-resistant prostate cancer. Eur Urol 2012, May; 61(5): 950-60.

[67] Brindle K. Watching tumours gasp and die with MRI: The promise of hyperpolarised 13C MR spectroscopic imaging. Br J Radiol 2012, Jun; 85(1014): 697-708.

[68] Rosen MA. Use of modified RECIST criteria to improve response assessment in targeted therapies: Challenges and opportunities. Cancer Biol Ther 2010, Jan; 9(1): 20-2.

[69] Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res 2007, Apr 15; 67(8): 3970-5.

[70] Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Quantitative analysis of tumor growth rate and changes in tumor marker level: Specific growth rate versus doubling time. Acta Oncol 2009; 48(4): 591-7.

[71] Mehrara E, Forssell-Aronsson E, Bernhardt P. Objective assessment of tumour response to therapy based on tumour growth kinetics. Br J Cancer 2011, Aug 23; 105(5): 682-6.

[72] Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007, Jun; 35(4): 495-516.

[73] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009, Jan; 45(2): 228-47.

[74] Weber WA. Assessing tumor response to therapy. J Nucl Med 2009, May; 50 Suppl 1:1S-10S.

[75] Le Tourneau C, Servois V, Dieras V, Ollivier L, Tresca P, Paoletti X. Tumour growth kinetics assessment: Added value to RECIST in cancer patients treated with molecu-larly targeted agents. Br J Cancer 2012, Feb 28; 106(5): 854-7.

[76] Ferte C, Albiges L, Soria JC, Loriot Y, Fizazi K, Escudier BJ. The use of tumor growth rate (TGR) in evaluating sorafenib and everolimus treatment in mrcc patients: An in tegrated analysis of the TARGET and RECORD phase III trials data. J Clin Oncol 30, 2012 (suppl; Abstr 4540).

[77] Motulsky H. Intuitive statistics a nonmathematical guide to statistical thinking. Second Ed. New York: Oxford University Press; 2010k.

[78] Nishida K, Kaneko T, Yoneda M, Nakagawa S, Ishikawa T, Yamane E, et al. Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis. J Surg Oncol 1999, Jul; 71(3): 140-6.

[79] Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006, Jun 20; 24(18): 2723-8.

[80] Srinivas S, Feldman D. A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res 2009, Sep; 29(9) : 3605-10.

[81] Hanninen M, Venner P, North S. A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Can Urol Assoc J 2009, Oct; 3(5): 369-74.

[82] De Crevoisier R, Slimane K, Messai T, Wibault P, Eschwege F, Bossi A, et al. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy. Ann Oncol 2010, Apr; 21(4): 808-14.

[83] Lee JH, Gulec SA, Kyshtoobayeva A, Sim MS, Morton DL. Biological factors, tumor growth kinetics, and survival after metastasectomy for pulmonary melanoma. Ann Surg Oncol 2009, Oct; 16(10): 2834-9.

Section 5

Medical Treatment

Chapter 10

Mole Removal

Mole Removal

Moles, warts, and other unsightly irregularities of the skin can be bothersome and even embarrassing. They can be removed naturally... Removing Warts and Moles Naturally! If you have moles, warts, and other skin irregularities that you cannot cover up affecting the way you look, you can have them removed. Doctors can be extremely expensive. Learn the natural ways you can remove these irregularities in the comfort of your own home.

Get My Free Ebook

Post a comment